Cooley represented Turnstone, and Latham & Watkins represented the underwriters in the IPO. Turnstone Biologics Corp. (Nasdaq: TSBX) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Cooley advised Angion on the deal. Angion, a clinical-stage biopharmaceutical company, announced its definitive merger agreement with Elicio Therapeutics. Elicio will merge with a wholly owned subsidiary...
You must be a Standard 1 Year member to access this content.
Cooley advised AN2 Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. AN2 Therapeutics, Inc. announced its upsized initial public offering of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...
You must be a Standard 1 Year member to access this content.
